This is a preview of subscription content, log in via an institution to check access.
Notes
2019 US dollars
Reference
Shah A, et al. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States ClinicoEconomics and Outcomes Research 2021: 789-800, No. 13, 10 Sep 2021. Available from: URL: https://doi.org/10.2147/CEOR.S310619
Rights and permissions
About this article
Cite this article
Budget impact of belantamab mafodotin in R/R multiple myeloma. PharmacoEcon Outcomes News 887, 8 (2021). https://doi.org/10.1007/s40274-021-08024-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08024-2